Bristol Myers Squibb's drug to treat a type of heart disease did not significantly improve functional capacity and symptoms ...

Mount Sinai's AI-powered ECG tool now predicts individual risk for hypertrophic cardiomyopathy (HCM), enabling faster ...

A team of US researchers, studying a type of heart disease known as hypertrophic cardiomyopathy (HCM) said they have ...

Researchers have calibrated an AI algorithm to more specifically identify patients with hypertrophic cardiomyopathy (HCM), a ...

According to analysts at BMO Capital Markets, non-obstructive hypertrophic cardiomyopathy would have meant a $1.3 billion ...

Mount Sinai researchers studying a type of heart disease known as hypertrophic cardiomyopathy (HCM) have calibrated an artificial intelligence (AI) algorithm to quickly and more specifically identify ...

Camzyos is an oral, selective allosteric and reversible inhibitor of cardiac myosin. It was approved in April 2022 for the treatment of adults with symptomatic New York Heart Association (NYHA) class ...

The result is a major disappointment for BMS as it effectively cuts the potential market for Camzyos in half. Sales of the ...

Bristol Myers Squibb announced that mavacamten did not achieve statistical significance in meeting the dual primary endpoints ...